Amicus Therapeutics, Inc.
US ˙ NasdaqGM ˙ US03152W1099

Introduction

This page provides a comprehensive analysis of the known insider trading history of David Michael Clark. Insiders are officers, directors, or significant investors in a company. It is illegal for insiders to make trades in their companies based on specific, non-public information. This does not mean it is illegal for them to make any trades in their own companies. However, they must report all trades to the SEC via a Form 4. Despite these restrictions, academic research suggests that insiders - in general - tend to outperform the market in their own companies.

Average Trade Profitability

The average trade profitability is the average return of all the open market purchases made by the insider in the last three years. To calculate this, we examine every open-market, unplanned purchase made by the insider, excluding all trades that were marked as part of a 10b5-1 trading plan. We then calculate the average performance of those trades over 3, 6, and 12 months, averaging each of those durations to generate a final performance metric for each trade. Finally, we average all of the performance metrics to calculate a performance metric for the insider. This list only includes insiders that have made at least three trades in the last two years.

If this insiders trade profitability is "N/A", then the insider either has not made any open-market purchases in the last three years, or the trades they’ve made are too recent to calculate a reliable performance metric.

Update Frequency: Daily

See the list of most profitable insider traders.

Companies with Reported Insider Positions

The SEC filings indicate David Michael Clark has reported holdings or trades in the following companies:

Security Title Latest Reported Holdings
US:FOLD / Amicus Therapeutics, Inc. Chief People Officer 348,261
How to Interpret the Charts

The following charts show the stock performance of securities subsequent to each open-market, non-planned trade made by David Michael Clark. Non-planned trade are trades that were not made as part of a 10b5-1 trading plan. The stock performance is charted as cumulative percent change in share price. For example, if an insider trade was made on January 1, 2019, the chart will show the daily percent change of the security to the present day. If the share price were to go from $10 to $15 during this time, the cumulative percent change in share price would be 50%. A change in price from $10 to $20 would be 100%, and a change in price of $10 to $5 would be -50%.

Ultimately, we are trying to determine how closely the insider’s trades correlate to excess returns (positive or negative) in the share price in order to see if the insider is timing their trades to profit from insider information. Consider the situation where an insider was doing this. In this situation, we would expect either (a) positive returns after purchases, or (b) negative returns after sales. In the case of (a), the PURCHASE chart would show a series of upwardly sloping curves, indicating positive returns after each purchase transaction. In the case of (b), the SALE chart would show a series of downward sloping curves, indicating negative returns after each sale transaction.

However, this alone is not enough to draw conclusions. If, for example, the share price of the company was in a non-cyclical climb over many years, then we would expect all the post-purchase plots to be upwardly sloping. Likewise, non-cyclical declines over many years would result in downward sloping post-trade plots. Neither of these charts would suggest insider trading activity.

The strongest indicator would be a situation where the share price was extremely cyclical, and there were both positive signals in the PURCHASE chart and negative plots on the SALE chart. This situation would be highly suggestive of an insider that was timing trades to their financial advantage.

Insider Purchases FOLD / Amicus Therapeutics, Inc. - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in FOLD / Amicus Therapeutics, Inc.. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Max
Price at
Max
Max
Profit ($)
Max Return (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

FOLD / Amicus Therapeutics, Inc. Insider Trades
Insider Sales FOLD / Amicus Therapeutics, Inc. - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in FOLD / Amicus Therapeutics, Inc.. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Min
Price at
Min
Max Loss
Avoided ($)
Max Loss
Avoided (%)
2024-02-15 FOLD Clark David Michael 4,427 14.0000 4,427 14.0000 61,978 330 9.0200 -22,046 -35.57
2024-01-09 FOLD Clark David Michael 1,384 14.0000 1,384 14.0000 19,376
2024-01-08 FOLD Clark David Michael 8,726 14.0000 8,726 14.0000 122,164

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

FOLD / Amicus Therapeutics, Inc. Insider Trades
Insider Trading History

This table shows the complete list of insider trades made by David Michael Clark as disclosed to the Securities Exchange Commission (SEC).

File Date Tran Date Form Ticker Security Code 10b5-1 Shares Remaining Shares Percent
Change
Share
Price
Tran
Value
Remaining
Value
2025-02-13 2025-02-11 4 FOLD AMICUS THERAPEUTICS, INC.
Common Stock
F - Taxes -20,593 348,261 -5.58 9.57 -197,075 3,332,858
2025-02-13 2025-02-11 4 FOLD AMICUS THERAPEUTICS, INC.
Common Stock
A - Award 52,338 368,854 16.54
2025-01-06 2025-01-04 4 FOLD AMICUS THERAPEUTICS, INC.
Common Stock
F - Taxes -2,692 316,516 -0.84 9.41 -25,332 2,978,416
2025-01-06 2025-01-03 4 FOLD AMICUS THERAPEUTICS, INC.
Common Stock
F - Taxes -11,987 319,208 -3.62 9.41 -112,798 3,003,747
2025-01-06 2025-01-03 4 FOLD AMICUS THERAPEUTICS, INC.
Common Stock
A - Award 69,228 331,195 26.43
2025-01-06 2025-01-02 4 FOLD AMICUS THERAPEUTICS, INC.
Common Stock
F - Taxes -5,381 261,967 -2.01 9.31 -50,097 2,438,913
2024-03-15 2024-01-09 4/A FOLD AMICUS THERAPEUTICS, INC.
Common Stock
F - Taxes -8,614 271,775 -3.07 13.65 -117,581 3,709,729
2024-03-15 2024-01-09 4/A FOLD AMICUS THERAPEUTICS, INC.
Common Stock
A - Award 13,684 280,389 5.13
2024-02-20 2024-02-15 4 FOLD AMICUS THERAPEUTICS, INC.
Common Stock
S - Sale -4,427 253,664 -1.72 14.00 -61,978 3,551,296
2024-01-11 2024-01-09 4 FOLD AMICUS THERAPEUTICS, INC.
Common Stock
F - Taxes -8,614 258,091 -3.23 13.65 -117,581 3,522,942
2024-01-09 2024-01-09 4 FOLD AMICUS THERAPEUTICS, INC.
Common Stock
S - Sale -1,384 266,705 -0.52 14.00 -19,376 3,733,870
2024-01-09 2024-01-08 4 FOLD AMICUS THERAPEUTICS, INC.
Common Stock
S - Sale -8,726 268,089 -3.15 14.00 -122,164 3,753,246
2024-01-05 2024-01-04 4 FOLD AMICUS THERAPEUTICS, INC.
Common Stock
F - Taxes -2,692 276,815 -0.96 13.44 -36,180 3,720,394
2024-01-04 2024-01-03 4 FOLD AMICUS THERAPEUTICS, INC.
Common Stock
F - Taxes -11,650 279,507 -4.00 13.53 -157,624 3,781,730
2024-01-04 2024-01-02 4 FOLD AMICUS THERAPEUTICS, INC.
Common Stock
F - Taxes -6,331 291,157 -2.13 14.24 -90,153 4,146,076
2024-01-04 2024-01-02 4 FOLD AMICUS THERAPEUTICS, INC.
Common Stock
A - Award 48,209 297,488 19.34
2023-12-19 2023-12-18 4 FOLD AMICUS THERAPEUTICS, INC.
Common Stock
A - Award 8,212 249,279 3.41
2023-01-19 2023-01-18 4 FOLD AMICUS THERAPEUTICS, INC.
Common Stock
S - Sale X -7,382 241,067 -2.97 13.50 -99,657 3,254,404
2023-01-13 2023-01-11 4 FOLD AMICUS THERAPEUTICS, INC.
Common Stock
F - Taxes -18,738 248,449 -7.01 12.02 -225,231 2,986,357
2023-01-13 2023-01-11 4 FOLD AMICUS THERAPEUTICS, INC.
Common Stock
A - Award 47,621 267,187 21.69
2023-01-06 2023-01-06 4 FOLD AMICUS THERAPEUTICS, INC.
Common Stock
S - Sale X -21,507 219,566 -8.92 11.87 -255,346 2,606,841
2023-01-06 2023-01-04 4 FOLD AMICUS THERAPEUTICS, INC.
Common Stock
F - Taxes -2,692 241,073 -1.10 12.03 -32,385 2,900,108
2023-01-04 2023-01-03 4 FOLD AMICUS THERAPEUTICS, INC.
Common Stock
F - Taxes -5,810 243,765 -2.33 11.93 -69,313 2,908,116
2023-01-04 2023-01-03 4 FOLD AMICUS THERAPEUTICS, INC.
Common Stock
A - Award 59,372 249,575 31.22
2023-01-04 2023-01-03 4 FOLD AMICUS THERAPEUTICS, INC.
Common Stock
S - Sale X -8,493 190,203 -4.27 12.03 -102,176 2,288,256
2023-01-04 2023-01-02 4 FOLD AMICUS THERAPEUTICS, INC.
Common Stock
F - Taxes -11,336 198,696 -5.40 12.21 -138,413 2,426,078
2022-10-11 2022-10-09 4 FOLD AMICUS THERAPEUTICS, INC.
Common Stock
F - Taxes -5,510 210,032 -2.56 10.40 -57,304 2,184,333
2022-08-09 2022-08-05 4 FOLD AMICUS THERAPEUTICS, INC.
Common Stock
S - Sale X -11,322 215,542 -4.99 12.50 -141,525 2,694,275
2022-01-19 2022-01-14 4 FOLD AMICUS THERAPEUTICS, INC.
Stock Options (right to buy)
A - Award 108,266 108,266
2022-01-19 2022-01-14 4 FOLD AMICUS THERAPEUTICS, INC.
Common Stock
F - Taxes -12,684 226,864 -5.29 10.53 -133,563 2,388,878
2022-01-19 2022-01-14 4 FOLD AMICUS THERAPEUTICS, INC.
Common Stock
A - Award 32,235 239,548 15.55
2022-01-19 2022-01-14 4 FOLD AMICUS THERAPEUTICS, INC.
Common Stock
A - Award 59,071 207,313 39.85
2022-01-04 2022-01-04 4 FOLD AMICUS THERAPEUTICS, INC.
Common Stock
F - Taxes -2,692 148,242 -1.78 12.48 -33,596 1,850,060
2022-01-04 2022-01-02 4 FOLD AMICUS THERAPEUTICS, INC.
Common Stock
F - Taxes -10,665 150,934 -6.60 11.55 -123,181 1,743,288
2022-01-04 2021-12-31 4 FOLD AMICUS THERAPEUTICS, INC.
Common Stock
F - Taxes -7,280 161,599 -4.31 11.55 -84,084 1,866,468
2021-10-12 2021-10-09 4 FOLD AMICUS THERAPEUTICS, INC.
Common Stock
F - Taxes -5,510 168,879 -3.16 11.51 -63,420 1,943,797
2021-04-08 2021-04-06 4 FOLD AMICUS THERAPEUTICS, INC.
Common Stock
A - Award 16,883 174,389 10.72
2021-01-05 2021-01-04 4 FOLD AMICUS THERAPEUTICS, INC.
Stock Options (right to buy)
A - Award 44,076 44,076
2021-01-05 2021-01-04 4 FOLD AMICUS THERAPEUTICS, INC.
Common Stock
A - Award 27,369 157,506 21.03
2021-01-05 2021-01-02 4 FOLD AMICUS THERAPEUTICS, INC.
Common Stock
F - Taxes -10,974 130,137 -7.78 23.09 -253,390 3,004,863
2020-10-20 2020-10-09 4 FOLD AMICUS THERAPEUTICS, INC.
Common Stock
F - Taxes -5,510 141,111 -3.76 15.12 -83,284 2,132,893
2020-02-14 2020-02-12 4 FOLD AMICUS THERAPEUTICS, INC.
Common Stock
S - Sale X -7,107 146,621 -4.62 11.00 -78,177 1,612,831
2020-01-06 2020-01-02 4 FOLD AMICUS THERAPEUTICS, INC.
Stock Options (right to buy)
A - Award 91,439 91,439
2020-01-06 2020-01-02 4 FOLD AMICUS THERAPEUTICS, INC.
Common Stock
F - Taxes -5,612 153,728 -3.52 9.55 -53,595 1,468,102
2020-01-06 2020-01-02 4 FOLD AMICUS THERAPEUTICS, INC.
Common Stock
A - Award 58,179 159,340 57.51
2019-10-10 2019-10-09 4 FOLD AMICUS THERAPEUTICS, INC.
Common Stock
F - Taxes -6,896 101,161 -6.38 7.48 -51,582 756,684
2019-01-10 2019-01-02 4 FOLD AMICUS THERAPEUTICS, INC.
Stock Options (right to buy)
A - Award 77,134 77,134
2019-01-10 2019-01-02 4 FOLD AMICUS THERAPEUTICS, INC.
Common Stock
A - Award 50,287 108,057 87.05
2018-10-11 2018-10-09 4 FOLD AMICUS THERAPEUTICS INC
Stock Options (right to buy)
A - Award 84,842 84,842
2018-10-11 2018-10-09 4 FOLD AMICUS THERAPEUTICS INC
Common Stock
A - Award 56,012 57,770 3,186.12
2018-10-11 3 FOLD AMICUS THERAPEUTICS INC
Common Stock
3,516
2018-10-11 3 FOLD AMICUS THERAPEUTICS INC
Common Stock
3,516
2018-10-11 3 FOLD AMICUS THERAPEUTICS INC
Common Stock
3,516
P
Open market or private purchase of non-derivative or derivative security
S
Open market or private sale of non-derivative or derivative security
A
Grant, award, or other acquisition of securities from the company (such as an option)
C
Conversion of derivative
D
Sale or transfer of securities back to the company
F
Payment of exercise price or tax liability using portion of securities received from the company
G
Gift of securities by or to the insider
K
Equity swaps and similar hedging transactions
M
Exercise or conversion of derivative security received from the company (such as an option)
V
A transaction voluntarily reported on Form 4
J
Other (accompanied by a footnote describing the transaction)